A fixed 15.5% manufacturer rebate on patented branded drugs replaces a proposed variable, expenditure-linked mechanism after coordinated industry pressure and threats to curtail German investment and ...

Pairing Tennr referral intake and documentation automation with TailorMed affordability tooling is designed to surface access barriers earlier and shorten time-to-therapy for infusion and specialty ...

Section 232 introduces a staged tariff regime: 100% default for patented drugs/APIs/KSMs, reduced 20% with approved onshoring plans, and temporary 0% if paired with MFN pricing until 2029. Deadlines ...

Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, explains which therapeutic areas will lead DTP adoption and her five-year outlook for the model. Direct-to-patient (DTP) programs are no ...

CMS-driven price relief may expand access, but adherence is the key determinant of durable cardiometabolic and weight outcomes in chronic-disease management. Discontinuation rates are high: roughly ...

PBM reform scrutiny of reimbursement, rebate flow, and compensation can shift benefit conditions that determine how manufacturer-funded copay, buy-down, and support programs function at dispensing.

As the US and Iran reach a framework agreement to reopen the Strait of Hormuz, Pharmaceutical Commerce breaks down what the deal means for pharmaceutical supply chains. By prioritizing solutions such ...